Estrogen dominance handout.pmd

PROVIDER HANDOUT
Estrogen Dominance
and Hormone Balance
The Condition
Many of the most common and unwanted symptoms of
Candidates
menopause and the years preceding it (peri-menopause) are causally connected to the condition of Estrogen Individuals in Menopause and/or with signs of low thyroid, Dominance, a term coined by John Lee, M.D., (What Your fibroids, endometriosis and overall symptoms of too much Doctor May Not Tell You About Menopause). The name estrogen including: breast tenderness, fibrocystic breasts, refers to a prolonged state of estrogen excess (particularly mood swings, vasomotor fluctuations, (hot flashes &/or in relation to progesterone) common to the waning of night sweats) irritability, anxiety, fat gain (hips and thighs) reproductive hormones with age, but exacerbated by exposure to the plethora of synthetic "xenohormones"such as HRT, pesticides and pollutants in our environment.
The Problem
Saliva testing is a simple, reliable means for detecting estrogen dominance as it measures only the fraction of The scientific literature is clear (www.salivatest.com for hormones that have left the bloodstream and are active complete references) that an excess of estrogen or in the tissues of the breast, uterus, brain, bones and estrogen activity at the cell level is a root cause of breast skin. This "bioavailable" measurement can detect long cancer. We know too, that hormone imbalances triggered hidden hormone imbalances and more closely correlates by the use of synthetic hormone combinations ( Premarin, with the clinical picture. Because hormones work Prempro, Premphase, Provera) can have deadly together to create a balanced internal milieu, its important consequences. The most recent definitive study, The to test all of the following to determine estrogen Womens Health Initiative Trial, was abruptly cancelled in July 2002 when it showed a greater risk vs. benefit for a · Estradiol (E2) the most potent of the estrogens
majority of diseases it was thought to be preventing: · Progesterone (Pg)
· A 41% increase in strokes
· Testosterone
· A 29% increase in heart attacks
· A 26% increase in breast cancer
· Cortisol (Adrenal Function)
· A 22% increase in total CVD
· A doubling of the rate of blood clots
Benefits
· A possible contributor to Alzheimer's disease
Key to hormone balance is the knowledge that when estrogen becomes the dominant hormone and progesterone is deficient, estrogen becomes toxic to In Premenopausal Women:
the body. At ZRT we monitor symptoms and hormone Ovulation or lack of (anovulation) followed by insufficient usage and relate these back to tested hormone levels to provide more diagnostic clues than are available with At PeriMenopause (30s-mid-50s):
standard tests. In this way, saliva testing can assist Lack of ovulation or erratic cycles, when estrogen levels detection of previously undiagnosed disorders, and serve fluctuate rapidly from high to low in the absence of as a rational basis for treatment to relieve symptoms PostMenopause:
An excess of estrogen to progesterone in waning reproductive years when ovarian production of estrogen declines up to 60% but progesterone levels can drop to nearly zero with the cessation of ovulation.
Estrogen dominance is a condition in which a woman can have 1815 NW 169th Place • Ste. 5050 • Beaverton, OR 97006 deficient, normal or excess estrogen but has little or no progesterone to Phone: (503) 466-2445 • Fax: (503) 466-1636 balance its effects upon the body.” Dr. John Lee, M.D. Author of What Toll-free: 1-866-600-1636 • info@zrtlab.com Your Doctor May Not Tell You About Menopause www.salivatest.com • www.bloodspottest.com Selected References
Principal Writing Group for the Women's Health Initiative Investigators Results from the Women’s Health Initiative (WHI) Randomized Controlled Trial JAMA 2002;288:321-333.
Cavalieri EL, Stack DE, et. al, Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initia- tors. Proc Natl Acad Sci U S A 1997 Sep 30;94(20):10937-42 Cowan LD, Gordis L, Tonascia JA, Jones GS Breast cancer incidence in women with a history of progesterone deficiency.
Cuzick J, Powles T, et. al,Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003 Jan Davis DL, Bradlow HL, et. al. Medical hypothesis: xenoestrogens as preventable causes of breast cancer.
Environ Health Perspect 1993 Oct;101(5):372-7 Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells Fertil Steril 1998 May;69(5):963-9 Formby B, Wiley TS, Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 1998 Nov-Dec;28(6):360-9 Formby B, Wiley TS. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem 1999 Dec;202(1- Graham JD, Clarke CL. Physiological action of progesterone in target tissues Endocr Rev 1997 Aug;18(4):502-19 Hofseth LJ, Raafat AM, et. al Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breastJ Clin Endocrinol Metab Lipworth L, Adami HO, et. al. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996 Jan;7(1):96-100 Mohr PE, Wang DY, et. al. Serum progesterone and prognosis in operable breast cancer. Br J Cancer 1996 Plu-Bureau G, Le MG, et. al. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Detect Prev 1999;23(4):290-6 Pujol P, Hilsenbeck SG, et al. Rising levels of estrogen receptor in breast cancer over 2 decade Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis.
`Sephton SE, Sapolsky RM, et. al. Diurnal cortisol rhythm as a predictor of breast cancer survival. Natl Cancer Inst Stoll BA Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr 1999 Grady D, Wenger NK, et. al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000 May 2;132(9):689-96 Grady D, Herrington D, et. al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002 Jul 3;288(1):49-57 Grodstein F, Manson JE, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000 Dec 19;133(12):933-41 Hsia J, Simon JA, et. al Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study Circulation 2000 Oct 31;102(18):2228-32 Hulley S, Grady D, et.al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA Low AK, Russell LD, et. al. Hormone replacement therapy and coronary heart disease in women: a review of the evidence. Am J Med Sci 2002 Oct;324(4):180-4 No authors listed Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA

Source: http://www.adamsdrugs.net/pharmacy-services/pdfs/Estrogen-Dominance.pdf